Work

Development of a Novel Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish and its use in Drug Discovery

Year: 2018
Type: article
Abstract: OKA), was dissolved in water and the zebrafish were housed in the water for a total of 9 days.This treatment resulted in the formation of many AD pathological hallmarks including cognitive decline, phosphorylation of tau, the formation of plaques, and the increase in kinase expression.The studies presented here were designed to further characterize the model and simultaneously use it as a drug screening tool.The first study showed that TDZD-8, a glycogen synthase kinase 3β (GSK3β) inhibitor, is able to treat the OKA-induced AD pathology by rescuing cognitive function, downregulating active GSK3β, downregulating pTau (Ser199), and normalizing protein phosphatase 2A activity.GSK3β has been established as a target for treating AD because of its role in phosphorylating tau.This study served as a proof of concept that the OKA-induced AD model in zebrafish can be utilized as a drug screen tool.The last studies demonstrated that a novel therapeutic, lanthionine ketimine-5-ethyl ester (LKE), is able to treat OKA insults by rescuing cognitive function and upregulating the BDNF/Akt/CREB pathway and reducing apoptosis in the zebrafish dorsal lateral pallium which is homologous to the human hippocampus.
Language: English
Open Access status: green
OpenAlex ID: W6990424467
FWCI:
Cites: 178
Cited by:
Related to: 10